scholarly journals Blockade of receptors of advanced glycation end products ameliorates diabetic osteogenesis of adipose-derived stem cells through DNA methylation and Wnt signalling pathway

2018 ◽  
Vol 51 (5) ◽  
pp. e12471 ◽  
Author(s):  
Maorui Zhang ◽  
Yong Li ◽  
Pengcheng Rao ◽  
Kui Huang ◽  
Daowen Luo ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Stem Cells ◽  
Advanced Glycation End Products ◽  
Wnt Signalling ◽  
Signalling Pathway ◽  
Adipose Derived Stem Cells ◽  
Advanced Glycation ◽  
Wnt Signalling Pathway ◽  
Glycation End Products ◽  
End Products

scholarly journals Advanced Glycation End Products Receptor DNA Methylation Is Associated with Immune Infiltration and Prognosis of Lung adenocarcinoma and lung squamous cell carcinoma

2021 ◽  
Author(s):  
Jun Yang ◽  
Xiaohui Chen ◽  
Mingqiang Lin ◽  
Mengyan Zhang ◽  
Zhiping Wang ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Squamous Cell Carcinoma ◽  
Lung Adenocarcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Advanced Glycation End Products ◽  
Lung Squamous Cell Carcinoma ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Abstract Background: Lung cancer has become the leading cause of cancer-related deaths worldwide with a rising trend of incidence and mortality. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) account for the major numbers, which should be paid enough attention. Advanced glycation end products receptor (AGER) is a multi-ligand receptor that interacts with a wide range of ligands. Previous studies have shown that abnormal AGER expression is closely related to immune infiltration and tumorigenesis. Nevertheless, the AGER DNA methylation relationship between prognosis and infiltrating immune cells in LUAD and LUSC is still unclear. Results: Compared with the normal lung tissues, the expression level of AGER was significantly reduced in LUAD and LUSC. Low expression of AGER was markedly correlated with histology, stage, lymph node metastasis and Tumor protein 53 (TP53) mutation and could be used as a potential indicator of poor prognosis of LUAD and LUSC. Further analysis showed that copy number variation (CNV), mutation and DNA methylation involved in the low level of AGER. Additionally, we found that AGER DNA hypermethylation meant a worse prognosis in LUAD and LUSC. In addition, we also found that hypermethylated AGER was significantly correlated with tumor infiltrating lymphocytes. Conclusion: AGER may be a candidate for the prognostic biomarker of LUAD and LUSC related with tumor immune microenvironment.

Stem Cells in Head and Neck Cancers Pathogenesis: Are Advanced Glycation End Products (AGEs) Involved?

2018 ◽  
Vol 04 (02) ◽  
Author(s):  
Petrescu Bianca Nausica ◽  
Babtan Anida Maria ◽  
Soritau Olga ◽  
Buhate Dan ◽  
Ionel Anca ◽  
...  
Keyword(s):  
Stem Cells ◽  
Head And Neck ◽  
Advanced Glycation End Products ◽  
Head And Neck Cancers ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties

2021 ◽  
Vol 10 (13) ◽  
pp. 2964
Author(s):  
Lize Evens ◽  
Ellen Heeren ◽  
Jean-Luc Rummens ◽  
Annelies Bronckaers ◽  
Marc Hendrikx ◽  
...  
Keyword(s):  
Stem Cells ◽  
Advanced Glycation End Products ◽  
Atrial Appendage ◽  
Advanced Glycation ◽  
Negative Effects ◽  
Glycation End Products ◽  
End Products ◽  
Negative Effect ◽  
Migration Capacity

Background: During myocardial infarction (MI), billions of cardiomyocytes are lost. The optimal therapy should effectively replace damaged cardiomyocytes, possibly with stem cells able to engraft and differentiate into adult functional cardiomyocytes. As such, cardiac atrial appendage stem cells (CASCs) are suitable candidates. However, the presence of elevated levels of advanced glycation end products (AGEs) in cardiac regions where CASCs are transplanted may affect their regenerative potential. In this study, we examine whether and how AGEs alter CASCs properties in vitro. Methods and Results: CASCs in culture were exposed to ranging AGEs concentrations (50 µg/mL to 400 µg/mL). CASCs survival, proliferation, and migration capacity were significantly decreased after 72 h of AGEs exposure. Apoptosis significantly increased with rising AGEs concentration. The harmful effects of these AGEs were partially blunted by pre-incubation with a receptor for AGEs (RAGE) inhibitor (25 µM FPS-ZM1), indicating the involvement of RAGE in the observed negative effects. Conclusion: AGEs have a time- and concentration-dependent negative effect on CASCs survival, proliferation, migration, and apoptosis in vitro, partially mediated through RAGE activation. Whether anti-AGEs therapies are an effective treatment in the setting of stem cell therapy after MI warrants further examination.

PPARγ-mediated advanced glycation end products regulation of neural stem cells

2009 ◽  
Vol 307 (1-2) ◽  
pp. 176-184 ◽  
Author(s):  
Shao-hua Wang ◽  
Zi-lin Sun ◽  
Yi-jing Guo ◽  
Yang Yuan ◽  
Ling Li
Keyword(s):  
Stem Cells ◽  
Neural Stem Cells ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document